“In the dynamic landscape of emerging clinical-stage therapies for patients with recurrent and metastatic head and neck squamous cell carcinoma, a significant unmet medical need remains despite the potential improvements in treatment options,” said Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology (PYXS). “We look forward to presenting our preliminary data from the ongoing clinical studies evaluating MICVO as a novel potential treatment option for recurrent and metastatic head and neck squamous cell carcinoma. We believe that the breadth of the MICVO clinical program, encompassing monotherapy and combination approaches, holds significant promise and this inflection point will further underscore our first-in-concept ADC’s potential to improve outcomes across multiple lines of therapy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology resumed with a Buy at Stifel
- Pyxis Oncology’s Promising Study on PYX-201 and Pembrolizumab in Advanced Solid Tumors
- Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment
- Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets
- Pyxis Oncology initiated with a Buy at Guggenheim